Hormone OptimizationResearch

GHRP-6 Therapy: Complete Guide

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone release by acting on the ghrelin receptor. It is one of the earlier GH-releasing peptides developed and is known for its potent appetite-stimulating effects alongside GH release. It is often used in combination with GHRH analogs for synergistic effects.

Typical cost: $80 - $250/month

Written by

Megan Williams

Editor-in-Chief

Reviewed by

Brian Williams

Co-founder & Research Editor

Last updated

May 26, 2026

What is GHRP-6?

What Is GHRP-6?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that acts as a potent growth hormone secretagogue (GHS) by activating the ghrelin/GHS receptor (GHS-R1a) in the pituitary gland. It was one of the first synthetic GH-releasing peptides developed and has been extensively studied since the early 1990s.

GHRP-6 was developed by Dr. Cyril Bowers and colleagues, who pioneered the field of growth hormone secretagogues. The peptide consists of six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) and potently stimulates GH release through a pathway distinct from GHRH.

Distinguishing Characteristics

GHRP-6 is notable for:

Potent GH release: One of the strongest peptide GH stimulators available
Appetite stimulation: Significant increase in hunger through ghrelin receptor activation — this can be a benefit or side effect depending on clinical goals
Gastric motility effects: Enhances gastrointestinal motility and gastric emptying
Cytoprotective properties: Emerging evidence for gastric mucosal protection

Clinical Applications

Growth hormone stimulation: For patients with age-related GH decline
Appetite stimulation: Useful in patients with poor appetite, cachexia, or need for caloric intake increase
Body composition: Supporting lean mass gain and fat reduction
Gastric protection: Potential cytoprotective applications
Recovery: Post-exercise and injury recovery through GH-mediated mechanisms

GHRP-6 is available through compounding pharmacies and peptide therapy clinics. While it is highly effective at stimulating GH release, the significant appetite stimulation it produces has led many practitioners to prefer ipamorelin for patients who do not need or want increased hunger.

How GHRP-6 Works

GHS Receptor Activation

GHRP-6 binds to and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. This receptor is expressed on pituitary somatotroph cells and in multiple brain regions.

GH Release Pathway

GHS-R1a activation by GHRP-6 triggers:

Phospholipase C activation in somatotroph cells
IP3/DAG-mediated calcium release from intracellular stores
Voltage-gated calcium channel activation
GH vesicle exocytosis — release of stored growth hormone

Somatostatin Suppression

GHRP-6 has an important additional mechanism: it partially suppresses somatostatin, the endogenous GH-inhibiting hormone. This dual action (direct GH stimulation + somatostatin suppression) makes GHRP-6 particularly effective and explains its synergy with GHRH analogs.

Appetite Stimulation

The GHS-R1a receptor in the hypothalamus (arcuate nucleus and ventromedial hypothalamus) mediates ghrelin's appetite-stimulating effects. GHRP-6 activates these same receptors, producing significant hunger that typically peaks 30–60 minutes after injection. This is a much stronger appetite effect than seen with ipamorelin or GHRP-2.

Cortisol and Prolactin Effects

Unlike the more selective ipamorelin, GHRP-6 also causes mild increases in cortisol and prolactin levels, particularly at higher doses. These effects are generally modest and transient but represent a reduced selectivity compared to newer GH secretagogues.

Benefits & Uses

Benefits of GHRP-6

Potent GH stimulation: GHRP-6 is one of the most potent peptide GH stimulators, producing significant and reliable increases in growth hormone levels. Studies show 3–6-fold increases in GH levels within 30 minutes of administration (Bowers et al., Endocrine Reviews, 1991).
Appetite stimulation: For patients who need to increase caloric intake — such as those with cachexia, wasting syndromes, or post-surgical recovery — GHRP-6's appetite-stimulating effect is a therapeutic benefit.
IGF-1 elevation: Sustained GHRP-6 use reliably increases IGF-1 levels, mediating many of the compound's anabolic and restorative effects.
Improved body composition: Through GH/IGF-1 axis stimulation, GHRP-6 supports increased lean muscle mass and reduced body fat with appropriate diet and exercise.
Enhanced recovery: GH-mediated improvements in protein synthesis and tissue repair support faster recovery from training and injury.
Sleep enhancement: Like other GH secretagogues, GHRP-6 enhances deep sleep quality when taken before bed.
Gastric cytoprotection: Research by Sibilia et al. (Endocrinology, 2006) showed that GHRP-6 and ghrelin have cytoprotective effects on gastric mucosa, reducing damage from various insults.
Synergy with GHRH analogs: When combined with CJC-1295 or sermorelin, GHRP-6 produces synergistic GH release greater than either compound alone.

Clinical Evidence & Research

Clinical and Preclinical Evidence

GH release characterization (Bowers et al., Endocrine Reviews, 1991): Foundational research establishing GHRP-6 as a potent GH secretagogue, with dose-dependent GH release and characterization of its receptor-mediated mechanism. This work was instrumental in defining the entire field of growth hormone secretagogues.

Synergy with GHRH (Bowers et al., Journal of Clinical Endocrinology & Metabolism, 1990): Demonstrated that combined administration of GHRP-6 with GHRH produced GH release substantially greater than either compound alone, establishing the pharmacological basis for combination protocols used in clinical practice.

Gastric cytoprotection (Sibilia et al., Endocrinology, 2006): Demonstrated that GHRP-6 and ghrelin receptor agonists protect gastric mucosa against ethanol-induced damage through vagus nerve-dependent and prostaglandin-mediated mechanisms.

Cardiac protection (Berlanga et al., Peptides, 2007): Animal studies showed that GHRP-6 reduced ischemia-reperfusion injury in cardiac tissue, suggesting potential cardioprotective applications beyond GH release.

GH secretagogue receptor research: GHRP-6 was instrumental in the discovery and characterization of the GHS-R1a receptor, ultimately leading to the identification of ghrelin as its endogenous ligand (Howard et al., Science, 1996).

"GHRP-6 played a pivotal role in the discovery of the growth hormone secretagogue receptor and the subsequent identification of ghrelin, fundamentally advancing our understanding of GH regulation." — Bowers, Journal of Clinical Endocrinology & Metabolism, 2001

Side Effects & Safety

Side Effect Profile

GHRP-6 is generally well-tolerated but has a broader side effect profile than the more selective ipamorelin.

Common Side Effects (Mild)

Intense hunger — The most characteristic side effect. Significant appetite increase occurs 30–60 minutes after injection and lasts 1–2 hours. This is much more pronounced than with GHRP-2 or ipamorelin.
Injection site reactions — Mild pain, redness, or swelling at the injection site.
Water retention — Mild fluid retention, particularly in the first 2–4 weeks.
Tingling/numbness — Transient paresthesias related to GH effects.

Less Common Side Effects (Moderate)

Cortisol elevation — Mild transient increase in cortisol levels, more pronounced at higher doses. Generally clinically insignificant but a point of differentiation from ipamorelin.
Prolactin elevation — Mild increase in prolactin levels at higher doses.
Headache — Occasionally reported; usually mild.
Dizziness — Rare; may relate to transient blood pressure changes.

Considerations

Weight gain risk: The strong appetite stimulation can lead to excessive caloric intake and weight gain if not managed with dietary discipline.
Blood sugar effects: GH can impair insulin sensitivity; monitoring is recommended for at-risk patients.

The significant appetite stimulation is the primary reason many practitioners and patients prefer ipamorelin for GH optimization, reserving GHRP-6 for situations where appetite enhancement is desired.

Dosing & Administration

Standard Dosing Protocols

GHRP-6 Alone

Dose: 100–300 mcg subcutaneously per injection
Frequency: 1–3 times daily
Timing: On an empty stomach; pre-bedtime, upon waking, and/or post-exercise

GHRP-6 + GHRH Analog Combination

GHRP-6: 100–200 mcg per injection
CJC-1295 (no DAC) or sermorelin: 100–200 mcg per injection
Frequency: 1–3 times daily, combined in the same injection

Administration: Subcutaneous injection in the abdominal area. Must be taken on an empty stomach (at least 2 hours after eating) as insulin and blood glucose blunt the GH response. Wait at least 30 minutes after injection before eating.

Cycle duration: Commonly used for 8–16 weeks with periodic breaks. Some practitioners prescribe 3–6 month cycles.

Clinical note: The intense hunger following GHRP-6 injection can be useful for those trying to gain weight/muscle but problematic for those targeting fat loss. Patients on fat-loss protocols may prefer ipamorelin. Timing the injection before a planned meal can help manage the appetite effect productively.

Find GHRP-6 Providers Near You

Search our directory for qualified providers offering GHRP-6 therapy. Filter by location, telehealth, and more.

Browse Providers

GHRP-6 FAQ

GHRP-6 activates the ghrelin receptor (GHS-R1a), which is the same receptor activated by ghrelin, the "hunger hormone." This receptor is present in hypothalamic appetite centers, and its activation is a powerful hunger stimulus. This effect is much stronger with GHRP-6 than with ipamorelin or GHRP-2 due to GHRP-6's potent activation of appetite-regulating neural circuits.

All three stimulate GH release through the ghrelin receptor, but they differ in selectivity. GHRP-6 produces the most hunger and has modest effects on cortisol and prolactin. GHRP-2 is slightly more potent for GH release with less hunger but still some cortisol elevation. Ipamorelin is the most selective, producing GH release without significant hunger, cortisol, or prolactin effects.

GHRP-6 supports muscle gain through two mechanisms: GH/IGF-1 stimulation (which enhances protein synthesis and tissue repair) and appetite stimulation (which helps achieve the caloric surplus needed for muscle growth). For individuals struggling to eat enough calories, GHRP-6's appetite effect can be particularly beneficial.

Yes, GHRP-6 must be taken on an empty stomach for optimal GH release. Elevated blood sugar and insulin from a recent meal significantly blunt the GH response. Wait at least 2 hours after eating before injecting, and wait at least 30 minutes after injection before eating, even though the hunger stimulus will be strong.

The cortisol increase from GHRP-6 is generally mild and transient, typically resolving within 1-2 hours. At standard doses, this elevation is not considered clinically significant for most patients. However, patients with cortisol-sensitive conditions or those already experiencing elevated cortisol may want to choose ipamorelin instead.